

For immediate release

Press Release

IOL Chemicals and Pharmaceuticals Ltd consistently reports strong performance in Q2' FY20

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted remarkable operational and financial performance for the second quarter of financial year 2019-20.

Quarter ended September 2019 vis a vis Quarter ended September 2018

- Income from operations increased by 5 % to ₹ 452 crore from ₹ 429 crore.
- EBIDTA increased by 68 % to ₹ 136 crore from ₹ 81 crore.
- Net Profit increased by 132 % to ₹ 88 crore from ₹ 38 crore.
- EPS increased by 125 % to ₹ 15.42 from ₹ 6.84.

Half year ended September 2019 vis a vis Half year ended September 2018

- Income from operations increased by 19 % to ₹ 948 crore from ₹ 794 crore.
- EBIDTA increased by 129 % to ₹ 284 crore from ₹ 124 crore.
- Net Profit increased by 226 % to ₹ 173 crore from ₹ 53 crore.
- EPS increased by 224 % to ₹ 30.42 from ₹ 9.40.

Mr Vijay Garg, Joint Managing Director said "We are very delighted to announce consistently strong operational and financial performance during the 2nd quarter of the Financial Year 2019-20. We have successfully set up Unit VI to manufacture Pantoprazole with a capacity of 240 MT per annum which will enable to increase the revenue of the Company. He further added, we have made the pre-payment of term loan of aggregate amount of ₹ 161.44 crore till date to reduce the financial cost of the Company."

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class



facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

